Godavari Biorefineries secures Chinese patent for viral infection treatment
- Godavari Biorefineries secured a Chinese patent for viral infection treatment compounds
- The patent covers compounds that inhibit V-ATPase activity in cells
- Grant date was September 15, 2026, following an application filed in May 2021
- The invention is registered under Godavari Biorefineries Limited based in Mumbai
*this image is generated using AI for illustrative purposes only.
Godavari Biorefineries has been granted a patent by the Chinese Patent Office for the use of specific compounds in treating viral infections. The intellectual property right was officially awarded on September 15, 2026.
The company disclosed the development in a regulatory filing dated September 16, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was addressed to the listing departments of both the National Stock Exchange of India Limited and BSE Limited.
Patent Details
The granted invention relates to the use of compounds for inhibiting V-ATPase activity in cells. This mechanism is further disclosed for its application in the manufacture of medicaments designed to treat viral infections. The patent application was originally filed on May 10, 2021.
| Detail | Information |
|---|---|
| Patent Title | Use of Compounds for Treating Viral Infections |
| Patent Number | ZL 2021 8 0048053.9 |
| Grant Date | September 15, 2026 |
| Application Date | May 10, 2021 |
| Inventors | M. Atwal, S. Gawade, P. Kakkar, S. Srivastava |
The inventors listed on the certificate are M. Atwal, S. Gawade, P. Kakkar, and S. Srivastava. The patent is registered under the name Godavari Biorefineries Limited, with the address listed as Mumbai, India.
What the Numbers Show
The five-year timeline between the initial application in May 2021 and the grant in September 2026 indicates a prolonged examination process typical for complex pharmaceutical patents in international jurisdictions. The successful grant validates the technical novelty of the V-ATPase inhibition approach within the Chinese regulatory framework, securing exclusive rights for the specified therapeutic use.
Historical Stock Returns for Godavari Biorefineries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +7.36% | -0.44% | -1.60% | -13.68% | -17.55% | -29.11% |
Will Godavari Biorefineries seek patent protection for this V-ATPase inhibition technology in other key markets like the US or EU to expand its global IP portfolio?
How might this patent grant influence the company's strategic partnerships or licensing negotiations with pharmaceutical firms specializing in antiviral treatments?
What is the current stage of clinical development for the compounds covered by this patent, and when can investors expect potential regulatory filings for drug approval?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
